Valantine Hannah sold $342K of BBIO

BridgeBio Pharma (BBIO) shares fell due to inclusion in the Medicaid Most Favored Nation pricing system, which investors fear will lead to price cuts. The decline is exacerbated by a broader biotech selloff and concerns over a recent shareholder offering. Despite growth in its Attruby franchise, the company faces regulatory and financial challenges, including significant losses and cash burn.

BridgeBio Pharma (BBIO) presented at the Morgan Stanley conference, highlighting growth driven by Attruby, which generated $222M in U.S. revenue last quarter. The company reported $100M quarterly losses, expects break-even by 2027-2028, and raised $1B in equity, boosting cash to $1.7B. Management anticipates three near-term drug launches and long-term value from its pipeline.

H.C. Wainwright reiterated a Buy rating on BridgeBio Pharma (BBIO) with a $120 price target, citing favorable data from a Phase 3 study. BBIO shares are up 44% over the past year, with revenue surging 202% in the last twelve months. The company reported Q2 2026 revenue of $243.7 million, exceeding estimates. Analysts from Piper Sandler, Canaccord, and Mizuho also raised their price targets.

BridgeBio Pharma (BBIO) reported Phase 3 PROPEL 3 trial results showing oral Infigratinib benefits in children with achondroplasia beyond growth, including sleep apnea and ear infections. The therapy reduced sleep apnea progression and ear infection rates compared to placebo, with improvements in body composition. Longer-term data showed sustained growth and proportionality improvements. BBIO filed a New Drug Application with the FDA and anticipates a U.S. launch in mid-2027. The stock closed at

BridgeBio (BBIO) reported Phase 3 study data showing some acoramidis-treated patients had cardiac improvements. 54% showed left ventricular function improvement at 30 months, per completer analysis. Separate analysis found 34% improvement. Treatment also reduced days lost to death or hospitalization. BridgeBio plans a Phase 3b/4 study to further evaluate acoramidis.

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.